Case Study

Pharmaceutical Company Running Phase 2 Study for Critically Ill COVID-19 Subjects Gets Unified Decentralized Platform

GettyImages-1288964081 dct study

At the start of the COVID-19 pandemic, a global eClinical provider was approached by a pharmaceutical sponsor with the request to provide a decentralized platform including eSource/ePRO for direct-data-entry, randomization, eConsent, telehealth, remote monitoring, and data management for a multisite trial for patients with SARS-CoV-2 in the hospital.

While the sponsor was looking for a team with decentralized clinical trial experience, they specifically needed a unified platform that could operate through one central login for all solutions. In addition to software solutions, they also needed a partner with data management capabilities.

Learn how this provider was able to deliver an experienced team, all working together to ensure rapid implementation and effective conduct services.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader